A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors [0.03%]
一项横断面研究：评估HIV-1感染者使用蛋白酶抑制剂与心血管疾病标志物、神经认知功能、骨矿物质密度和肾脏标志物之间高胆红素血症关联性研究报告
T J Barber,G Moyle,A Hill et al.
T J Barber et al.
Background: Ongoing inflammation in controlled HIV infection contributes to non-AIDS comorbidities. High bilirubin appears to exhibit an anti-inflammatory effect in vivo. We therefore examined whether increased bilirubin ...
Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients [0.03%]
土耳其HIV-1感染者整合酶 strand transfer 抑制剂（INSTI）耐药突变分析
M Sayan,A Gündüz,G Ersöz et al.
M Sayan et al.
Objectives: Integrase strand transfer inhibitor (INSTI) is a new class of antiretroviral (ARV) drugs designed to block the action of the integrase viral enzyme, which is responsible for insertation of the HIV-1 genome int...
Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study [0.03%]
fosamprenavir/ritonavir用于病毒性肝炎合并感染患者的观察型多队列研究
Paola Nasta,Dominique Salmon,Antonella d&#x;Arminio Monforte et al.
Paola Nasta et al.
Objective: Safety and tolerability evaluation of adapted dose regimens containing fosamprenavir/ritonavir (FPV/r) in HIV-infected subjects with viral hepatitis co-infection. ...
Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy [0.03%]
从洛匹那韦/利托那韦联合两种核苷[酸]类似物逆转录酶抑制剂转换为洛匹那韦/利托那韦联合拉米夫定对骨密度的影响：OLE-LIP分支研究结果
M Crespo,J Navarro,M Martinez-Rebollar et al.
M Crespo et al.
Objective: To compare 48-week changes in bone mineral density (BMD) and body fat distribution between patients continuing lopinavir/ritonavir and two NRTIs and those switching to lopinavir/ritonavir and lamivudine. ...
Clinical Trial
HIV clinical trials. 2016 May;17(3):89-95. DOI:10.1080/15284336.2016.1149929 2016
Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study [0.03%]
关于博赛普韦联合聚乙二醇干扰素α与利巴韦林治疗HIV和基因1型丙肝病毒共感染患者的疗效，安全性及药代动力学：ANRS HC27研究数据
Isabelle Poizot-Martin,Eric Bellissant,Rodolphe Garraffo et al.
Isabelle Poizot-Martin et al.
Background: Scarce data exist on the efficacy and safety of the PEGylated-interferon/ribavirin/boceprevir regimen in HIV/HCV-coinfected patients who failed to respond to PEGylated-interferon/ribavirin treatment. ...
Clinical Trial
HIV clinical trials. 2016 Mar;17(2):63-71. DOI:10.1080/15284336.2015.1135553 2016
Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation [0.03%]
重组人生长激素和罗格列酮对HIV相关性腹部脂肪蓄积患者血清脂联素及炎症指标的影响
Vivien Leung,Ya-Lin Chiu,Donald P Kotler et al.
Vivien Leung et al.
Background/objective: In a previous report of HIV-infected patients with fat redistribution, we found that recombinant human growth hormone (rhGH) therapy reduced visceral adipose tissue (VAT) but increased insulin resist...
Randomized Controlled Trial
HIV clinical trials. 2016 Mar;17(2):55-62. DOI:10.1080/15284336.2015.1126424 2016
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial [0.03%]
利托那韦-达芦伟林与阿扎那韦-利托那韦对HIV感染者胰岛素敏感性影响的48周研究：一项Ⅳ期随机临床试验（METABOLIK试验）探索性亚组分析结果
Edgar Turner Overton,Pablo Tebas,Bruce Coate et al.
Edgar Turner Overton et al.
Background: The phase 4, METABOLIK trial demonstrated that changes in metabolic parameters with darunavir with low-dose ritonavir (DRV/r) were comparable to those observed with atazanavir with low-dose ritonavir (ATV/r). ...
Clinical Trial
HIV clinical trials. 2016 Mar;17(2):72-7. DOI:10.1080/15284336.2016.1141468 2016
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study [0.03%]
SWITCH研究中基线存在人免疫缺陷病毒(HIV-1)耐药突变且已实现病毒学抑制的患者换用利匹韦林/恩曲他滨/富马酸替诺福韦二吡呋酯后的临床结局
Danielle P Porter,Jonathan Toma,Yuping Tan et al.
Danielle P Porter et al.
Objectives: Antiretroviral regimen switching may be considered for HIV-1-infected, virologically-suppressed patients to enable treatment simplification or improve tolerability, but should be guided by knowledge of pre-exi...
Clinical Trial
HIV clinical trials. 2016 Feb;17(1):29-37. DOI:10.1080/15284336.2015.1115585 2016
Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study [0.03%]
一项关于治疗初治HIV-1感染患者的阿扎那韦/利托那韦抗逆转录病毒疗法长期疗效、耐受性和肾安全性的队列研究（REMAIN研究）
Eugénio Teófilo,Nuno Rocha-Pereira,Birger Kuhlmann et al.
Eugénio Teófilo et al.
Background: Boosted protease inhibitors (PIs), including ritonavir-boosted atazanavir (ATV/r), are a recommended option for the initial treatment of HIV-1 infection based upon clinical trial data; however, long-term real-...
Clinical Trial
HIV clinical trials. 2016 Feb;17(1):17-28. DOI:10.1080/15284336.2015.1112494 2016
Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles [0.03%]
初治患者开始抗病毒治疗后血浆病毒载量反弹的时间及其耐药谱分析
Frederic Crouzat,Anita C Benoit,Colin Kovacs et al.
Frederic Crouzat et al.
Background: The resistance profiles for patients on first-line antiretroviral therapy (ART) regimens after viremia have not been well studied in community clinic settings in the modern treatment era. ...